Joseph Catanzaro
Stock Analyst at Piper Sandler
(2.22)
# 1,540
Out of 4,412 analysts
61
Total ratings
37.29%
Success rate
-1.43%
Average return
Main Sectors:
30 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics | Maintains: Overweight | $26 → $30 | $8.46 | +254.61% | 2 | Apr 25, 2024 | |
| BOLD Boundless Bio | Initiates: Overweight | $20 | $11.64 | +71.82% | 1 | Apr 22, 2024 | |
| ACHL Achilles Therapeutics | Downgrades: Neutral | $8 → $2 | $0.76 | +163.16% | 3 | Apr 5, 2024 | |
| KROS Keros Therapeutics | Maintains: Overweight | $105 | $57.86 | +81.47% | 2 | Mar 27, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Overweight | $28 | $15.72 | +78.12% | 1 | Mar 27, 2024 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $40 | $14.92 | +168.10% | 4 | Mar 26, 2024 | |
| IBRX ImmunityBio | Maintains: Neutral | $4 → $5 | $7.35 | -31.97% | 2 | Mar 25, 2024 | |
| IMAB I-Mab | Maintains: Overweight | $15 → $10 | $1.80 | +455.56% | 4 | Mar 18, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $18 → $19 | $11.64 | +63.23% | 6 | Mar 14, 2024 | |
| RVMD Revolution Medicines | Initiates: Overweight | $43 | $35.96 | +19.58% | 1 | Mar 11, 2024 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $5 → $7 | $4.07 | +71.99% | 3 | Mar 1, 2024 | |
| SDGR Schrödinger | Maintains: Overweight | $60 → $50 | $23.97 | +108.59% | 2 | Feb 29, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $10 → $15 | $4.75 | +216.12% | 3 | Feb 26, 2024 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $18 | $7.44 | +141.94% | 1 | Feb 12, 2024 | |
| AADI Aadi Bioscience | Maintains: Overweight | $30 → $5 | $1.75 | +185.71% | 2 | Dec 15, 2023 | |
| RPTX Repare Therapeutics | Maintains: Overweight | $30 → $25 | $3.20 | +681.25% | 3 | Oct 16, 2023 | |
| TSBX Turnstone Biologics | Initiates: Overweight | $20 | $2.76 | +624.64% | 1 | Aug 15, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $100 | $65.42 | +52.86% | 2 | Jul 24, 2023 | |
| BDTX Black Diamond Therapeutics | Initiates: Overweight | $11 | $5.89 | +86.76% | 1 | Jul 14, 2023 | |
| BMEA Biomea Fusion | Maintains: Overweight | $40 → $45 | $10.78 | +317.44% | 3 | Jun 26, 2023 | |
| EXEL Exelixis | Assumes: Overweight | $28 | $23.70 | +18.14% | 1 | May 10, 2023 | |
| HALO Halozyme Therapeutics | Upgrades: Overweight | $46 | $38.57 | +19.26% | 3 | May 10, 2023 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Overweight | $18 → $20 | $14.89 | +34.32% | 1 | Dec 20, 2022 | |
| CTMX CytomX Therapeutics | Downgrades: Neutral | $10 → $1.5 | $1.59 | -5.66% | 1 | Jul 7, 2022 | |
| EPIX ESSA Pharma | Maintains: Overweight | $50 → $20 | $6.08 | +228.95% | 1 | May 12, 2022 | |
| CNTB Connect Biopharma Holdings | Downgrades: Neutral | $25 → $1.5 | $1.34 | +11.94% | 1 | May 5, 2022 | |
| SNSE Sensei Biotherapeutics | Maintains: Overweight | $12 → $10 | $1.02 | +880.39% | 2 | Mar 10, 2022 | |
| FIGS FIGS, Inc. | Initiates: Overweight | n/a | $4.92 | - | 1 | Jun 21, 2021 | |
| MRKR Marker Therapeutics | Initiates: Overweight | n/a | $4.30 | - | 1 | Mar 25, 2021 | |
| XBIT XBiotech | Maintains: Overweight | n/a | $7.87 | - | 2 | Apr 7, 2020 |
Acrivon Therapeutics
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $8.46
Upside: +254.61%
Boundless Bio
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $11.64
Upside: +71.82%
Achilles Therapeutics
Apr 5, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.76
Upside: +163.16%
Keros Therapeutics
Mar 27, 2024
Maintains: Overweight
Price Target: $105
Current: $57.86
Upside: +81.47%
LENZ Therapeutics
Mar 27, 2024
Initiates: Overweight
Price Target: $28
Current: $15.72
Upside: +78.12%
Day One Biopharmaceuticals
Mar 26, 2024
Maintains: Overweight
Price Target: $40
Current: $14.92
Upside: +168.10%
ImmunityBio
Mar 25, 2024
Maintains: Neutral
Price Target: $4 → $5
Current: $7.35
Upside: -31.97%
I-Mab
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $1.80
Upside: +455.56%
Iovance Biotherapeutics
Mar 14, 2024
Maintains: Overweight
Price Target: $18 → $19
Current: $11.64
Upside: +63.23%
Revolution Medicines
Mar 11, 2024
Initiates: Overweight
Price Target: $43
Current: $35.96
Upside: +19.58%
Cardiff Oncology
Mar 1, 2024
Maintains: Overweight
Price Target: $5 → $7
Current: $4.07
Upside: +71.99%
Schrödinger
Feb 29, 2024
Maintains: Overweight
Price Target: $60 → $50
Current: $23.97
Upside: +108.59%
Ocular Therapeutix
Feb 26, 2024
Maintains: Overweight
Price Target: $10 → $15
Current: $4.75
Upside: +216.12%
Tango Therapeutics
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $7.44
Upside: +141.94%
Aadi Bioscience
Dec 15, 2023
Maintains: Overweight
Price Target: $30 → $5
Current: $1.75
Upside: +185.71%
Repare Therapeutics
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $3.20
Upside: +681.25%
Turnstone Biologics
Aug 15, 2023
Initiates: Overweight
Price Target: $20
Current: $2.76
Upside: +624.64%
Gilead Sciences
Jul 24, 2023
Maintains: Overweight
Price Target: $105 → $100
Current: $65.42
Upside: +52.86%
Black Diamond Therapeutics
Jul 14, 2023
Initiates: Overweight
Price Target: $11
Current: $5.89
Upside: +86.76%
Biomea Fusion
Jun 26, 2023
Maintains: Overweight
Price Target: $40 → $45
Current: $10.78
Upside: +317.44%
Exelixis
May 10, 2023
Assumes: Overweight
Price Target: $28
Current: $23.70
Upside: +18.14%
Halozyme Therapeutics
May 10, 2023
Upgrades: Overweight
Price Target: $46
Current: $38.57
Upside: +19.26%
Catalyst Pharmaceuticals
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $14.89
Upside: +34.32%
CytomX Therapeutics
Jul 7, 2022
Downgrades: Neutral
Price Target: $10 → $1.5
Current: $1.59
Upside: -5.66%
ESSA Pharma
May 12, 2022
Maintains: Overweight
Price Target: $50 → $20
Current: $6.08
Upside: +228.95%
Connect Biopharma Holdings
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.34
Upside: +11.94%
Sensei Biotherapeutics
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $1.02
Upside: +880.39%
FIGS, Inc.
Jun 21, 2021
Initiates: Overweight
Price Target: n/a
Current: $4.92
Upside: -
Marker Therapeutics
Mar 25, 2021
Initiates: Overweight
Price Target: n/a
Current: $4.30
Upside: -
XBiotech
Apr 7, 2020
Maintains: Overweight
Price Target: n/a
Current: $7.87
Upside: -